WallStSmart

Allurion Technologies, Inc. (ALUR)vsDexCom Inc (DXCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 28777% more annual revenue ($4.97B vs $17.21M). DXCM leads profitability with a 20.1% profit margin vs -1.9%. DXCM earns a higher WallStSmart Score of 74/100 (B).

ALUR

Avoid

34

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0

DXCM

Strong Buy

74

out of 100

Grade: B

Growth: 8.0Profit: 8.5Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.67

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALUR1 strengths · Avg: 10.0/10
EPS GrowthGrowth
71.2%10/10

Earnings expanding 71.2% YoY

DXCM4 strengths · Avg: 8.8/10
Return on EquityProfitability
38.1%10/10

Every $100 of equity generates 38 in profit

Profit MarginProfitability
20.1%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
24.3%8/10

Strong operational efficiency at 24.3%

EPS GrowthGrowth
43.6%8/10

Earnings expanding 43.6% YoY

Areas to Watch

ALUR4 concerns · Avg: 2.5/10
Market CapQuality
$8.96M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-0.5%2/10

Revenue declined 0.5%

Free Cash FlowQuality
$-6.54M2/10

Negative free cash flow — burning cash

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.9x4/10

Trading at 11.9x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ALUR

The strongest argument for ALUR centers on EPS Growth.

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.

Bear Case : ALUR

The primary concerns for ALUR are Market Cap, Return on Equity, Revenue Growth.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Key Dynamics to Monitor

ALUR profiles as a turnaround stock while DXCM is a mature play — different risk/reward profiles.

DXCM carries more volatility with a beta of 1.42 — expect wider price swings.

DXCM is growing revenue faster at 13.1% — sustainability is the question.

DXCM generates stronger free cash flow (185M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (74/100 vs 34/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Allurion Technologies, Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. The company is headquartered in Natick, Massachusetts.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Want to dig deeper into these stocks?